Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
作者信息
Katsiki Niki, Banach Maciej, Mikhailidis Dimitri P
机构信息
First Department of Internal Medicine, Diabetes Centre, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece.
Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
出版信息
Arch Med Sci. 2020 Apr 14;16(3):485-489. doi: 10.5114/aoms.2020.94503. eCollection 2020.
Abstract
摘要
相似文献
1
Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.2019冠状病毒病大流行时代的降脂治疗与肾素-血管紧张素-醛固酮系统抑制剂
Arch Med Sci. 2020 Apr 14;16(3):485-489. doi: 10.5114/aoms.2020.94503. eCollection 2020.
2
The renin angiotensin aldosterone system and COVID-19.肾素-血管紧张素-醛固酮系统与新型冠状病毒肺炎
Saudi Pharm J. 2020 Aug;28(8):977-984. doi: 10.1016/j.jsps.2020.06.019. Epub 2020 Jul 2.
3
Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.肾素-血管紧张素-醛固酮系统的抑制作用：聚焦于阿利吉仑。
J Assoc Physicians India. 2010 Feb;58:102-8.
4
First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.首个口服活性直接肾素抑制剂阿利吉仑——高血压及其他疾病治疗的新前景。
Indian Heart J. 2010 Jan-Feb;62(1):49-56.
5
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.血浆醛固酮和C反应蛋白水平与新型冠状病毒肺炎的严重程度：Dyhor-19研究
J Clin Med. 2020 Jul 21;9(7):2315. doi: 10.3390/jcm9072315.
6
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.使用培多美索治疗可降低慢性肾脏病和肾素-血管紧张素系统抑制剂治疗高钾血症患者的醛固酮水平。
Kidney Int. 2016 Sep;90(3):696-704. doi: 10.1016/j.kint.2016.04.019. Epub 2016 Jun 24.
7
Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.在服用RAAS抑制剂的高级别胶质瘤患者的治疗方案中添加低剂量复方新诺明用于预防肺孢子菌肺炎时实验室干扰风险的评估。
J Oncol Pharm Pract. 2019 Sep;25(6):1366-1373. doi: 10.1177/1078155218792985. Epub 2018 Aug 19.
8
Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.慢性肾素-血管紧张素-醛固酮系统抑制剂治疗的脓毒性休克患者使用血管加压素的评估
Crit Care Med. 2017 Dec;45(12):e1226-e1232. doi: 10.1097/CCM.0000000000002729.
9
The renin-angiotensin-aldosterone system and heart failure.肾素-血管紧张素-醛固酮系统与心力衰竭。
Cardiol Clin. 2014 Feb;32(1):21-32, vii. doi: 10.1016/j.ccl.2013.09.002.
10
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.针对有使用肾素-血管紧张素-醛固酮抑制剂指征患者的高钾血症新疗法：试验设计与监管批准的考量
Int J Cardiol. 2016 Aug 1;216:46-51. doi: 10.1016/j.ijcard.2016.04.127. Epub 2016 Apr 19.
引用本文的文献
1
Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.弥合心血管疾病与新冠病毒疾病之间的差距：氧化型低密度脂蛋白假说。
Front Med (Lausanne). 2025 Aug 6;12:1588062. doi: 10.3389/fmed.2025.1588062. eCollection 2025.
2
New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.COVID-19 中的新发糖尿病：一项范围综述
Diabetes Ther. 2024 Jan;15(1):33-60. doi: 10.1007/s13300-023-01465-7. Epub 2023 Sep 26.
3
Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study.早期淋巴细胞计数降低会增加新冠病毒肺炎患者的病情严重程度和死亡风险：一项基于医院的病例队列研究
Arch Med Sci. 2020 Sep 15;19(5):1303-1313. doi: 10.5114/aoms.2020.99006. eCollection 2023.
4
Bioactive lipid-based therapeutic approach to COVID-19 and other similar infections.基于生物活性脂质的新冠病毒及其他类似感染的治疗方法。
Arch Med Sci. 2021 Apr 23;19(5):1327-1359. doi: 10.5114/aoms/135703. eCollection 2023.
5
The Effects and Outcomes of the COVID-19 Pandemic on Pregnant Women in Kuwait.新冠疫情对科威特孕妇的影响及结果
Med Princ Pract. 2023 Sep 14;32(4-5):260-71. doi: 10.1159/000534125.
6
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
7
Hepatic Anti-Oxidative Genes and Are Epigenetically Modulated by RORγ/NRF2 in Alphacoronavirus-Exposed Piglets.甲型冠状病毒感染的仔猪肝脏抗氧化基因受RORγ/NRF2的表观遗传调控。
Antioxidants (Basel). 2023 Jun 19;12(6):1305. doi: 10.3390/antiox12061305.
8
Changing Face of Inflammatory Activation in Complex Coronary Artery Disease during the COVID-19 Pandemic.新冠疫情期间复杂冠状动脉疾病中炎症激活情况的变化
J Cardiovasc Dev Dis. 2023 Apr 30;10(5):199. doi: 10.3390/jcdd10050199.
9
Is COVID-19 another case of the obesity paradox? Results from an international ecological study on behalf of the REPROGRAM Consortium Obesity study group.新型冠状病毒肺炎是肥胖悖论的又一实例吗？一项代表REPROGRAM联盟肥胖研究小组开展的国际生态学研究结果。
Arch Med Sci. 2021 May 10;19(1):25-34. doi: 10.5114/aoms/136447. eCollection 2023.
10
The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对脂质代谢的影响——降脂药物在2019冠状病毒病（COVID-19）治疗中的潜在应用
Biomedicines. 2022 Sep 18;10(9):2320. doi: 10.3390/biomedicines10092320.
本文引用的文献
1
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
2
Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.华盛顿州金县长期护理机构中 COVID-19 的流行病学。
N Engl J Med. 2020 May 21;382(21):2005-2011. doi: 10.1056/NEJMoa2005412. Epub 2020 Mar 27.
3
Are certain drugs associated with enhanced mortality in COVID-19?某些药物是否与新冠病毒疾病（COVID-19）死亡率升高有关？
QJM. 2020 Jul 1;113(7):509-510. doi: 10.1093/qjmed/hcaa103.
4
Potential Effects of Coronaviruses on the Cardiovascular System: A Review.冠状病毒对心血管系统的潜在影响：综述。
JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.
5
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
6
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations.新型冠状病毒肺炎死亡率与肾素-血管紧张素系统之间是否存在关联？呼吁开展流行病学研究。
Clin Infect Dis. 2020 Jul 28;71(15):870-874. doi: 10.1093/cid/ciaa329.
7
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.中国武汉 2019 年冠状病毒病死亡和康复病例的临床特征：回顾性研究。
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267. doi: 10.1097/CM9.0000000000000824.
8
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.心血管考虑因素在 COVID-19 大流行期间的患者、医护人员和卫生系统。
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
9
Clinical features and treatment of COVID-19 patients in northeast Chongqing.重庆东北部地区 COVID-19 患者的临床特征和治疗方法。
J Med Virol. 2020 Jul;92(7):797-806. doi: 10.1002/jmv.25783. Epub 2020 Apr 1.
10
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.藏而不露：治疗重症 COVID-19 感染患者的方法。
mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
Zotero 插件